- Cara Therapeutics (NASDAQ:CARA) resumed with Buy rating and $22 (53% upside) price target at H.C. Wainwright.
- Mirati Therapeutics (NASDAQ:MRTX) initiated with Overweight rating and $44 (27% upside) price target at Barclays (LON:BARC).
- Fennec Pharmaceuticals (NASDAQ:FENC) initiated with Outperform rating and $17 (81% upside) price target at Wedbush.
- Motus GI Holdings (Pending:MOTS) initiated with Outperform rating and $7 (40% upside) price target at Oppenheimer.
- Taro Pharmaceutical Industries (NYSE:TARO) initiated with Buy rating and $124 (24% upside) price target at H.C. Wainwright.
- Genfit SA (OTCPK:GNFTF) initiated with Buy rating and €105 price target at H.C. Wainwright.
- Otonomy (NASDAQ:OTIC) upgraded to Overweight at Piper Jaffray.
- Aratana Therapeutics (NASDAQ:PETX) upgraded to Buy at CL King.
- Express Scripts (NASDAQ:ESRX) upgraded to Market Perform at Bernstein.
- Voyager Therapeutics (NASDAQ:VYGR) downgraded to Neutral at Wedbush. Downgraded to In-line at Evercore ISI.
- Denali Therapeutics (NASDAQ:DNLI) downgraded to In-line at Evercore ISI.
- REGENXBIO (NASDAQ:RGNX) downgraded to In-line at Evercore ISI.
- Now read: Avisol's February Theme Of The Month: NASH, Its Causes, And Genfit Focus
Original article